Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion ...

Rallybio (NASDAQ:RLYB) stock soars 114% after agreeing to sell its stake in a rare bone disorder asset, extending cash runway to mid-2027. Read more here.

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.72, moving +2.24% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.28%.

While you can pick up the very basics of JavaScript in a day, becoming truly good at it takes much longer. Think of it like ...

The Google API Client Library for JavaScript is designed for JavaScript client-application developers. It offers simple, flexible access to many Google APIs. Note: This repo does not contain the ...